Study of PG2 Injection for Improving Fatigue in Patients After Palliative Abdominal Surgery for Cancer
Launched by PHYTOHEALTH CORPORATION · Mar 2, 2014
Trial Information
Current as of June 06, 2025
Withdrawn
Keywords
ClinConnect Summary
This will be a double-blind, randomized, and placebo-controlled study. At least 40 evaluable patients who are scheduled for palliative abdominal surgery for cancer will be randomly assigned to the control or treatment group. Each group will have at least 20 patients and be treated as follows: 1) control group: patients will accept placebo 1 dose a day (POD-1) before surgery and 1 dose a day for 3 days after surgery (POD+0 to POD+2); 2) treatment group: patients will accept PG2 1 dose a day (POD-1) before surgery and 1 dose a day for 3 days after surgery (POD+0 to POD+2).
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients who have cancer and are scheduled for palliative abdominal surgery for cancer
- • Age \> 20 years older
- • Patients who signed the informed consent form
- Exclusion Criteria:
- • Patients, at screening, has levels greater than 2.5 times the upper limit of normal liver function of alanine aminotransferase or aspartate aminotransferase.
- • Patients has a severe renal impairment (defined as serum creatinine greater than 2 times the upper limit of normal or BUN greater than 2.5 times the upper limit of normal for range); or the subject is on dialysis.
- • Patients have ongoing infection, respiratory tract dysfunction, cardiac dysfunction or immune disorder that, in the opinion of the investigator, may interfere with conduct of the study.
- • Patients who are not suitable for undergoing surgery (e.g. congenital hemostatic disorders) by the investigator's judgment.
- • Patients have enrolled or have not yet completed other investigational drug trials within 1 month before screening.
- • Female patients are pregnant or breast-feeding.
- • Patients who require preoperative nutritional support
- • Patients with serious comorbidities (American Society of Anesthesiologists Risk Class of 4 or 5).
- • Patients who is unwilling or unable to answer the quality of life questionnaires i.e. the BFI-T and EORTC QLQ-C30.
About Phytohealth Corporation
PhytoHealth Corporation is a leading biopharmaceutical company dedicated to advancing innovative therapies derived from plant-based compounds. With a strong commitment to research and development, PhytoHealth focuses on harnessing the potential of phytomedicine to address unmet medical needs across various therapeutic areas. The company prioritizes rigorous clinical trials and scientific validation to ensure the safety and efficacy of its products, aiming to improve patient outcomes and enhance the quality of life. Through collaboration with academic institutions and healthcare professionals, PhytoHealth is at the forefront of transforming traditional medicine into evidence-based solutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Taipei, , Taiwan
Taipei, , Taiwan
Patients applied
Trial Officials
Jin-Ming Wu, M.D.
Principal Investigator
National Taiwan University Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials